Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Fluorodeoxyglucose F18
Gallium Radioisotopes
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
Prospective Studies
Radiopharmaceuticals
Receptors, Urokinase Plasminogen Activator
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
68Ga-NOTA-AE105
PET/CT
head and neck cancer
prognostication
risk stratification
urokinase-type plasminogen activator receptor
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
09
08
2021
accepted:
16
11
2021
pubmed:
4
12
2021
medline:
4
8
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
The aim of this phase II clinical trial (NCT02965001) was to evaluate the prognostic value of urokinase-type plasminogen activator receptor (uPAR) PET/CT with the novel ligand
Identifiants
pubmed: 34857658
pii: jnumed.121.262866
doi: 10.2967/jnumed.121.262866
pmc: PMC9364350
doi:
Substances chimiques
Gallium Radioisotopes
0
Radiopharmaceuticals
0
Receptors, Urokinase Plasminogen Activator
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Banques de données
ClinicalTrials.gov
['NCT02965001']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1169-1176Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Theranostics. 2015 Sep 13;5(12):1303-16
pubmed: 26516369
BMC Cancer. 2017 Aug 25;17(1):572
pubmed: 28841839
Nucl Med Biol. 2013 Jul;40(5):618-24
pubmed: 23602763
PET Clin. 2017 Apr;12(2):243-255
pubmed: 28267457
Lancet Oncol. 2016 Apr;17(4):440-451
pubmed: 26936027
Head Neck. 2016 Apr;38 Suppl 1:E1863-9
pubmed: 26749143
Acta Oncol. 2018 Sep;57(9):1143-1151
pubmed: 29447088
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Med Res Rev. 2014 Sep;34(5):918-56
pubmed: 24549574
Oncotarget. 2017 Sep 8;8(54):92090-92105
pubmed: 29190900
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60
pubmed: 10837935
Theranostics. 2013 Aug 03;3(9):618-32
pubmed: 24052804
Head Neck. 2015 Sep;37(9):1274-81
pubmed: 24801812
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149561
Clin Microbiol Rev. 2016 Apr;29(2):291-319
pubmed: 26912568
Head Neck. 2021 Aug;43(8):2477-2487
pubmed: 33955080
Insights Imaging. 2014 Oct;5(5):585-602
pubmed: 25154759
Semin Nucl Med. 2021 Jan;51(1):13-25
pubmed: 33246535
Cancer Treat Rev. 2008 Apr;34(2):122-36
pubmed: 18162327
Nucl Med Biol. 2012 May;39(4):560-9
pubmed: 22172391
PET Clin. 2017 Jul;12(3):311-319
pubmed: 28576169
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
J Clin Oncol. 2012 Jun 10;30(17):2102-11
pubmed: 22565003
Diagnostics (Basel). 2020 Dec 01;10(12):
pubmed: 33271785
Nucl Med Biol. 2014 Mar;41(3):290-5
pubmed: 24533988
Br J Cancer. 2019 Apr;120(8):827-833
pubmed: 30890775
J Nucl Med. 2012 Jan;53(1):138-45
pubmed: 22213823
PLoS One. 2012;7(12):e51862
pubmed: 23251644
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Int J Health Care Qual Assur. 2012;25(2):145-9
pubmed: 22455179
Clin Physiol Funct Imaging. 2013 Sep;33(5):329-37
pubmed: 23701192
J Nucl Med. 2017 Mar;58(3):379-386
pubmed: 27609788
Head Neck. 2016 Apr;38 Suppl 1:E246-55
pubmed: 25546527
Oncotarget. 2017 Feb 28;8(9):15407-15419
pubmed: 28039488
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Sci Rep. 2017 Dec 1;7(1):16715
pubmed: 29196639